FARMERS & MERCHANTS TRUST Co OF LONG BEACH Lowers Position in Johnson & Johnson (NYSE:JNJ)

FARMERS & MERCHANTS TRUST Co OF LONG BEACH trimmed its stake in Johnson & Johnson (NYSE:JNJ) by 1.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 28,544 shares of the company’s stock after selling 535 shares during the period. Johnson & Johnson makes up approximately 1.0% of FARMERS & MERCHANTS TRUST Co OF LONG BEACH’s portfolio, making the stock its 23rd biggest holding. FARMERS & MERCHANTS TRUST Co OF LONG BEACH’s holdings in Johnson & Johnson were worth $4,128,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Pacer Advisors Inc. boosted its holdings in shares of Johnson & Johnson by 15.3% in the 2nd quarter. Pacer Advisors Inc. now owns 240,605 shares of the company’s stock worth $35,167,000 after purchasing an additional 31,908 shares in the last quarter. Kowal Investment Group LLC grew its position in Johnson & Johnson by 1.2% during the second quarter. Kowal Investment Group LLC now owns 9,888 shares of the company’s stock valued at $1,445,000 after acquiring an additional 121 shares during the last quarter. ProShare Advisors LLC raised its stake in shares of Johnson & Johnson by 9.8% during the second quarter. ProShare Advisors LLC now owns 1,651,733 shares of the company’s stock worth $241,417,000 after acquiring an additional 147,609 shares in the last quarter. Prospector Partners LLC lifted its holdings in shares of Johnson & Johnson by 1.0% in the 2nd quarter. Prospector Partners LLC now owns 66,134 shares of the company’s stock worth $9,666,000 after acquiring an additional 660 shares during the last quarter. Finally, Frank Rimerman Advisors LLC grew its holdings in shares of Johnson & Johnson by 1,811.6% during the 2nd quarter. Frank Rimerman Advisors LLC now owns 31,541 shares of the company’s stock valued at $4,610,000 after purchasing an additional 29,891 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Performance

Johnson & Johnson stock opened at $147.03 on Monday. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $168.85. The stock’s 50 day simple moving average is $148.51 and its two-hundred day simple moving average is $156.03. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The stock has a market cap of $353.99 billion, a price-to-earnings ratio of 21.28, a PEG ratio of 2.30 and a beta of 0.51.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.37%. Johnson & Johnson’s payout ratio is 71.78%.

Analyst Ratings Changes

Several analysts have weighed in on the stock. Wolfe Research initiated coverage on shares of Johnson & Johnson in a research note on Friday, November 15th. They issued an “outperform” rating and a $190.00 price target for the company. Guggenheim increased their target price on Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. Wells Fargo & Company lifted their price target on Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 16th. Royal Bank of Canada increased their price objective on Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research note on Wednesday, October 16th. Finally, Morgan Stanley lifted their target price on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 16th. Seven investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus target price of $174.29.

Insiders Place Their Bets

In other Johnson & Johnson news, Director Mark A. Weinberger acquired 1,000 shares of the business’s stock in a transaction on Thursday, December 12th. The shares were acquired at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the acquisition, the director now owns 1,000 shares in the company, valued at $147,220. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.16% of the stock is owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.